Nefro Avillion Clinical Development

Nefro Avillion is a clinical development company and a subsidiary of Avillion, established specifically to advance the development of therapies in the nephrology space. The company operates under Avillion's unique co-development model, where it provides funding and clinical expertise to accelerate the late-stage development of partnered assets. Its primary focus has been the Phase 3 clinical program for vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, for the treatment of anemia associated with chronic kidney disease. By managing the clinical execution and regulatory path, Nefro Avillion aims to bring critical renal treatments to market more efficiently.